Daniel Brennan
Stock Analyst at TD Cowen
(1.79)
# 3,148
Out of 4,876 analysts
20
Total ratings
33.33%
Success rate
4.6%
Average return
Main Sectors:
Stocks Rated by Daniel Brennan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QTRX Quanterix | Maintains: Hold | $14 → $16 | $6.65 | +140.60% | 2 | Nov 13, 2024 | |
| LAB Standard BioTools | Maintains: Buy | $2.75 → $2.5 | $1.19 | +110.08% | 3 | Oct 31, 2024 | |
| AVTR Avantor | Maintains: Buy | $30 → $29 | $13.53 | +114.34% | 5 | Oct 8, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Buy | $12 → $2.5 | $1.29 | +93.80% | 2 | Apr 17, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $613 → $670 | $408.28 | +64.10% | 1 | Feb 2, 2023 | |
| CRL Charles River Laboratories International | Upgrades: Buy | $177 → $200 | $150.01 | +33.32% | 2 | May 13, 2020 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $755 → $770 | $1,184.54 | -35.00% | 2 | May 8, 2020 | |
| EXAS Exact Sciences | Maintains: Buy | $135 → $115 | $53.65 | +114.35% | 3 | Apr 28, 2020 |
Quanterix
Nov 13, 2024
Maintains: Hold
Price Target: $14 → $16
Current: $6.65
Upside: +140.60%
Standard BioTools
Oct 31, 2024
Maintains: Buy
Price Target: $2.75 → $2.5
Current: $1.19
Upside: +110.08%
Avantor
Oct 8, 2024
Maintains: Buy
Price Target: $30 → $29
Current: $13.53
Upside: +114.34%
Pacific Biosciences of California
Apr 17, 2024
Maintains: Buy
Price Target: $12 → $2.5
Current: $1.29
Upside: +93.80%
Thermo Fisher Scientific
Feb 2, 2023
Maintains: Overweight
Price Target: $613 → $670
Current: $408.28
Upside: +64.10%
Charles River Laboratories International
May 13, 2020
Upgrades: Buy
Price Target: $177 → $200
Current: $150.01
Upside: +33.32%
Mettler-Toledo International
May 8, 2020
Maintains: Neutral
Price Target: $755 → $770
Current: $1,184.54
Upside: -35.00%
Exact Sciences
Apr 28, 2020
Maintains: Buy
Price Target: $135 → $115
Current: $53.65
Upside: +114.35%